• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

    5/20/22 8:00:28 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care
    Get the next $CVET alert in real time by email
    SC 13D/A 1 d330843dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    Covetrus, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    22304C100

    (CUSIP Number)

    CD&R VFC Holdings, L.P.

    c/o Clayton, Dubilier & Rice, LLC

    Attention: Rima Simson

    375 Park Avenue

    New York NY 10152

    (212) 407-5227

    with a copy to:

    Debevoise & Plimpton LLP

    Attention: Nicholas P. Pellicani, Esq.

    919 Third Avenue

    New York, NY 10022

    (212) 909-6000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    May 19, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box  ☐.

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 22304C100

     

      1.    

      NAME OF REPORTING PERSON

     

      CD&R VFC HOLDINGS, L.P.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC

      5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      CAYMAN ISLANDS

    Number of Shares Beneficially Owned by Each Reporting Person With

     

         7.    

      SOLE VOTING POWER

     

      33,670,541 (see Item 5)

         8.  

      SHARED VOTING POWER

     

      0

         9.  

      SOLE DISPOSITIVE POWER

     

      33,670,541 (see Item 5)

       10.  

      SHARED DISPOSITIVE POWER

     

      0

    11.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      33,670,541 (see Item 5)

    12.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      24.15% (see Item 5)1

    14.  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

     

    1 

    Based on 139,405,751 shares of Common Stock outstanding as of April 29, 2022, based on the Issuer’s Form 10-Q for the quarter ended March 31, 2022, filed on May 5, 2022.

     

    2


    CUSIP No. 22304C100

     

      1.    

      NAME OF REPORTING PERSON

     

      CD&R INVESTMENT ASSOCIATES IX, LTD.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC

      5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      CAYMAN ISLANDS

    Number of Shares Beneficially Owned by Each Reporting Person With

     

         7.    

      SOLE VOTING POWER

     

      33,670,541 (see Item 5)

         8.  

      SHARED VOTING POWER

     

      0

         9.  

      SOLE DISPOSITIVE POWER

     

      33,670,541 (see Item 5)

       10.  

      SHARED DISPOSITIVE POWER

     

      0

    11.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      33,670,541

    12.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      24.15% (see Item 5)1

    14.  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO

     

     

    1 

    Based on 139,405,751 shares of Common Stock outstanding as of April 29, 2022, based on the Issuer’s Form 10-Q for the quarter ended March 31, 2022, filed on May 5, 2022.

     

    3


    EXPLANATORY NOTE

    This Amendment No. 4 amends the Statement on Schedule 13D (“Schedule 13D”) initially filed on February 11, 2019 with the U.S. Securities and Exchange Commission and amended by Amendment No. 1 filed on May 1, 2020, Amendment No. 2 filed on May 20, 2020 and Amendment No. 3 filed on November 20, 2020 by (i) CD&R VFC Holdings, L.P., a Cayman Islands exempted limited partnership (“CD&R Holdings”), and (ii) CD&R Investment Associates IX, Ltd., a Cayman Islands exempted company (“CD&R Holdings GP” and, together with CD&R Holdings, the “Reporting Persons”).

    ITEM 2. IDENTITY AND BACKGROUND.

    Schedule A of the Schedule 13D is hereby amended and restated in its entirety in the form attached hereto and incorporated by reference herein.

    ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

    Item 3 of the Schedule 13D is hereby supplemented to include the following information:

    To finance the transaction contemplated by the Proposal (as defined below), affiliates of the Reporting Persons and of TPG Global, LLC (“TPG”) expect to enter into one or more debt commitment letters with third parties and equity commitment letters with their managed investment funds. Any third party financing for the transactions contemplated by the Proposal remains subject to negotiation of definitive agreements on terms acceptable to the Sponsors (as defined below). It is anticipated that a portion of the funding for the Proposal will be equity financing in the form of rollover equity from CD&R Holdings.

    ITEM 4. PURPOSE OF TRANSACTION.

    Item 4 of the Schedule 13D is hereby supplemented to include the following information:

    On May 19, 2022, Clayton, Dubilier & Rice, LLC and TPG (together, the “Sponsors”) submitted a letter setting forth a non-binding proposal to acquire all of the outstanding shares of Common Stock of the Issuer that are not owned by the Sponsors or their affiliates for cash consideration of $21.00 per share of Common Stock (the “Proposal”) to a transaction committee of the board of directors of the Issuer (the “Board”) comprised of non-management directors that are independent of the Reporting Persons and their affiliates (the “Transaction Committee”).

    The Proposal does not create any legal obligations and no such obligations will arise unless and until definitive transaction documentation with the Issuer has been executed and delivered. No binding obligation on the part of the Reporting Persons or any of their affiliates will arise with respect to the filing of this Schedule 13D. While the Proposal remains under consideration by the Transaction Committee, the Reporting Persons and their affiliates expect to respond to inquiries from, and negotiate the terms of the Proposal with, the Transaction Committee and its representatives. The Reporting Persons do not intend to provide additional disclosures regarding the Proposal until a definitive agreement has been reached or unless disclosure is otherwise required under applicable U.S. securities laws. Affiliates of the Reporting Persons and of TPG also expect to continue to engage in discussions and negotiations with potential financing sources and enter into one or more definitive debt commitment letters with third parties and equity commitment letters with their managed investment funds.

    The Proposal may result in one or more of the transactions, events or actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, including, without limitation, an acquisition of additional securities of the Issuer, an extraordinary corporate transaction (such as a merger) involving the Issuer, delisting of the Common Stock from the Nasdaq Global Select Market and other material changes in the Issuer’s business or corporate structure.

    Prior to the making of the Proposal, on May 19, 2022, the Issuer granted CD&R Holdings a limited waiver (the “Limited Waiver”) of the standstill restrictions contained in the Investment Agreement in order to permit the submission of the Proposal, as well as to permit CD&R Holdings to pursue, develop and, if later approved by the Board upon the recommendation of the Transaction Committee, enter into the transaction contemplated by the Proposal.

     

    4


    No assurances can be given that a definitive agreement will be reached or that the transaction contemplated by the Proposal will be consummated. The Sponsors reserve the right to modify or withdraw the Proposal at any time. Subject to the restrictions set forth in the Investment Agreement, as modified by the Limited Waiver, the Reporting Persons reserve the right to formulate other plans or make other proposals which could result in one or more of the transactions, events or actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, and to modify or withdraw any such plan or proposal at any time. Subject to the restrictions set forth in the Investment Agreement, as modified by the Limited Waiver, if the transaction contemplated by the Proposal is not consummated, the Reporting Persons and their affiliates will continue to regularly review and assess their investment in the Issuer and, depending on market conditions and other factors, may determine, from time to time, to engage in any of the events set forth in clauses (a) through (j) of Item 4 of Schedule 13D.

    The foregoing descriptions of the Proposal and the Limited Waiver do not purport to be complete and are subject to, and qualified in its entirety by, the full text of such documents, which are attached hereto as Exhibits 99.8 and 99.9, respectively.

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

    Item 5 of the Schedule 13D is hereby amended by deleting paragraphs (a)(i), (b) and (c) in their entirety and replacing them as follows:

    (a)    

    (i) CD&R Holdings is the beneficial owner and direct holder of 33,670,541 shares of Common Stock. 11,066,478 of such shares of Common Stock were acquired by CD&R Holdings on February 7, 2019 in connection with the Merger, 14,357,478 of such shares of Common Stock were issued on September 9, 2020 upon conversion of 159,368 shares of the Issuer’s 7.5% Series A Convertible Preferred Stock (the “Series A Preferred Stock”), at the option of the Issuer, pursuant to the terms of the Certificate of Designations, and 8,246,585 of such shares of Common Stock were issued on November 18, 2020 upon conversion by the Issuer of 90,632 shares of Series A Preferred Stock, at the option of the Issuer, pursuant to the terms of the Certificate of Designations and following approval by the Issuer’s stockholders on November 17, 2020 of the conversion of all outstanding shares of Series A Preferred Stock into Common Stock, which included accrued dividends in respect of the 90,632 shares of Series A Preferred Stock in the form of 81,540 shares of Common Stock. CD&R Holdings’ ownership interest is approximately 24.15% of the outstanding shares of Common Stock, based on 139,405,751 shares of Common Stock outstanding as of April 29, 2022, as reported in the Issuer’s Form 10-Q, filed with the SEC on May 5, 2022.

    (b) In addition to the description set forth above in Item 5(a), see the cover pages of this Schedule 13D for indications of the respective voting powers and disposition powers of the Reporting Persons.

    (c) Except as otherwise described in Item 5 of this Schedule 13D, each of the Reporting Persons reports that neither it, nor to its knowledge, any other person named in Schedule A of this Schedule 13D, has effected any transactions in shares of Common Stock in the past 60 days.

    ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

    Item 6 of the Schedule 13D is hereby supplemented to incorporate by reference the information set forth in Item 4 above.

     

    5


    ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

     

    Exhibit Number

      

    Description of Exhibit

    99.8    Letter, dated May 19, 2022, from the Sponsors to the Transaction Committee
    99.9    Limited Waiver, dated May 19, 2022
    99.10    Joint Filing Agreement

     

    6


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: May 20, 2022

     

    CD&R VFC HOLDINGS, L.P.
            By:  

    CD&R Investment Associates IX, Ltd.,

    its general partner

       
      By:  

    /s/ Rima Simson

        Name: Rima Simson
        Title: Vice President, Treasurer and Secretary
    CD&R INVESTMENT ASSOCIATES IX, LTD.
      By:  

    /s/ Rima Simson

        Name: Rima Simson
        Title: Vice President, Treasurer and Secretary

     

    7


    SCHEDULE A

    The business address for each of the persons listed below is c/o Clayton, Dubilier & Rice, LLC, 375 Park Avenue, 18th Floor, New York, New York 10152, and the business telephone number of each such person is 212-407-5200.

     

    Name

      

    Title/Principal Occupation or Employment

      

    Citizenship

    Donald J. Gogel    Mr. Gogel is a director and officer of CD&R Investment Associates IX, Ltd.    United States of America
    Nathan K. Sleeper    Mr. Sleeper is a director and officer of CD&R Investment Associates IX, Ltd.    United States of America
    Richard J. Schnall    Mr. Schnall is an officer of CD&R Investment Associates IX, Ltd.    United States of America
    David A. Novak    Mr. Novak is an officer of CD&R Investment Associates IX, Ltd.    United States of America
    Rima Simson    Ms. Simson is an officer of CD&R Investment Associates IX, Ltd.    United States of America
    Jessie Pamas    Ms. Pamas is an officer of CD&R Investment Associates IX, Ltd.    United States of America
    Theresa A. Gore    Ms. Gore is an officer of CD&R Investment Associates IX, Ltd.    United States of America
    Jillian C. Griffiths    Ms. Griffiths is an officer of CD&R Investment Associates IX, Ltd.    United States of America

     

     

    8

    Get the next $CVET alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVET

    DatePrice TargetRatingAnalyst
    6/13/2022$22.00Buy → Hold
    Stifel
    5/23/2022Outperform → Mkt Perform
    Raymond James
    11/18/2021$19.00Equal-Weight
    Morgan Stanley
    11/5/2021$37.00 → $27.00Outperform
    Raymond James
    8/9/2021$46.00 → $38.00Overweight
    Barclays
    8/6/2021$38.00 → $37.00Outperform
    Raymond James
    8/5/2021$29.00Neutral
    Credit Suisse
    7/12/2021$30.00Neutral → Buy
    Guggenheim
    More analyst ratings

    $CVET
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

      Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

      8/8/24 9:00:00 AM ET
      $SEMR
      $CVET
      Computer Software: Prepackaged Software
      Technology
      Other Pharmaceuticals
      Health Care
    • Westlake Set to Join S&P MidCap 400; MillerKnoll to Join S&P SmallCap 600

      NEW YORK, Oct. 13, 2022 /PRNewswire/ -- Westlake Corp. (NYSE:WLK) will replace MillerKnoll Inc. (NASD:MLKN) in the S&P MidCap 400, and MillerKnoll will replace Covetrus Inc. (NASD:CVET) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 18. Clayton, Dubilier & Rice and TPG Capital acquired Covetrus in a deal that closed today. MillerKnoll is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 18, 2022 S&P MidCap 400 Addition Westlake WLK Materials S&P MidCap 400 Deletion Miller

      10/13/22 5:50:00 PM ET
      $CVET
      $MLKN
      $SPGI
      $WLK
      Other Pharmaceuticals
      Health Care
      Office Equipment/Supplies/Services
      Consumer Discretionary
    • Covetrus Names Michelle Bonfilio as Chief People Officer

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

      9/26/22 4:00:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    SEC Filings

    See more
    • SEC Form 15-12G filed by Covetrus Inc.

      15-12G - COVETRUS, INC. (0001752836) (Filer)

      10/24/22 11:12:59 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Covetrus Inc.

      S-8 POS - COVETRUS, INC. (0001752836) (Filer)

      10/13/22 11:19:58 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13E3/A filed by Covetrus Inc. (Amendment)

      SC 13E3/A - COVETRUS, INC. (0001752836) (Subject)

      10/13/22 11:17:50 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Covetrus downgraded by Stifel with a new price target

      Stifel downgraded Covetrus from Buy to Hold and set a new price target of $22.00

      6/13/22 7:15:59 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus downgraded by Raymond James

      Raymond James downgraded Covetrus from Outperform to Mkt Perform

      5/23/22 7:13:08 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Morgan Stanley initiated coverage on Covetrus with a new price target

      Morgan Stanley initiated coverage of Covetrus with a rating of Equal-Weight and set a new price target of $19.00

      11/18/21 8:28:56 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Financials

    Live finance-specific insights

    See more
    • Covetrus Announces Financial Results for Second Quarter of 2022

      Second quarter 2022 net sales of $1.22 billion, an increase of 2% year-over-year; GAAP net loss attributable to Covetrus of $(4) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA was flat year-over-year at $66 million, including a $2 million year-over-year headwind from the strengthening of the U.S. Dollar First half 2022 net sales of $2.37 billion, an increase of 3% year-over-year; GAAP net loss attributable to Covetrus of $(6) million Non-GAAP organic net sales growth of 6% year-over-year Non-GAAP adjusted EBITDA increased 5% year-over-year to $129 million, including a $4 million year-over-year headwind from the strengthening of the U.S.

      8/4/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces First Quarter 2022 Earnings Release Date and Conference Call Information

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, announced today that it will release first quarter 2022 results after the market closes on Thursday, May 5, 2022. Following the release, the Company will hold a conference call at 4:30 PM ET, during which Ben Wolin, president and chief executive officer, and Matthew Foulston, executive vice president and chief financial officer, will review the results. To access the live webcast of the conference call and the corresponding slide presentation, individuals can register at our Investor Relations site: https://ir.covetrus.com/investors/events-and-presentations. An archived edition of the conference call will be

      4/29/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces Financial Results for Fourth Quarter and Full-Year of 2021

      Fourth quarter 2021 net sales of $1.12 billion, unchanged year-over-year; GAAP net loss attributable to Covetrus of $(3) million Non-GAAP organic net sales growth of 2% year-over-year Non-GAAP adjusted EBITDA increased 13% year-over-year to $63 million Full-year 2021 net sales of $4.58 billion, an increase of 5% year-over-year; GAAP net loss attributable to Covetrus of $(54) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA increased 8% year-over-year to $244 million 2022 non-GAAP organic net sales growth guidance of 7% to 8% and non-GAAP adjusted EBITDA guidance in the range of $270 million to $280 million Covetrus® (NASDAQ:CVET), a

      2/24/22 4:01:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cd&R Investment Associates Ix, Ltd. disposed of 33,670,541 shares

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:44:56 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Helton Sandra L returned 38,095 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:08:02 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Laskawy Philip A returned 15,064 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:07:42 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Leadership Updates

    Live Leadership Updates

    See more
    • Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

      Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

      8/8/24 9:00:00 AM ET
      $SEMR
      $CVET
      Computer Software: Prepackaged Software
      Technology
      Other Pharmaceuticals
      Health Care
    • Covetrus Names Michelle Bonfilio as Chief People Officer

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

      9/26/22 4:00:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Names Margie B. Pritchard General Counsel

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben Wolin, President and Chief Executive Officer (CEO) at Covetrus. Prior to being named as General Counsel, Pritchard most recently served as Vice President, Deputy Counsel at Covetrus, where she was responsible for corporate and board governance, public reporting, advising investor relations, employment matters including compensation, and providing general legal counsel to executive management. "Margie has been serving as Interim General Counsel since December 2021, and we are thrilled to have h

      8/26/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

      SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

      10/13/22 11:50:30 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

      SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

      5/25/22 12:15:30 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

      SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

      5/20/22 8:00:28 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care